Conference Coverage

Certolizumab Eased Skin and Joint Symptoms in PsA

Publish date: June 13, 2012

 

FROM THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY

Dr. Mease reported financial relation ships with UCB, which markets certolizumab. In addition, as a clinical trialist he has financial relationships with numerous other pharmaceutical companies that are interested in rheumatologic diseases.

Pages

Recommended Reading

Lung Infections More Common Among Anti-TNF Users
MDedge Dermatology
HIV Infection Complicates Rheumatologic Treatments and Vice Versa
MDedge Dermatology
Panel Recommends Tofacitinib Approval for Refractory RA
MDedge Dermatology
Biologics for RA Do Not Increase Solid Cancer Risk
MDedge Dermatology
Avoid Certain Vaccine-Biologic Combos
MDedge Dermatology
Smokers Less Likely to Respond to Biologic Treatment for RA
MDedge Dermatology
Could a Urine Test Predict Response to Biologics?
MDedge Dermatology
High-Dose Ustekinumab Stomps Out Palmoplantar Psoriasis
MDedge Dermatology
RA Patient Feedback Suggests Criteria Fall Short
MDedge Dermatology
Weight Contributes to Anti-TNF Response in PsA
MDedge Dermatology